Identification of a Bona Fide MicroRNA Biomarker in Serum Exosomes That Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Jan 14

PMID 25584485

Citations 171

Authors

K Sugimachi

T Matsumura

H Hirata

R Uchi

M Ueda

H Ueo

Y Shinden

T Iguchi

H Eguchi

K Shirabe

T Ochiya

Y Maehara

K Mimori

Affiliations

Soon will be listed here.

Abstract

Background: Predictive biomarkers for the recurrence of hepatocellular carcinoma (HCC) have great benefit in the selection of treatment options, including liver transplantation (LT), for HCC. The purpose of this study was to identify specific microRNAs (miRs) in exosomes from the serum of patients with recurrent HCC and to validate these molecules as novel biomarkers for HCC recurrence.

Methods: We employed microarray-based expression profiling of miRs derived from exosomes in the serum of HCC patients to identify a biomarker that distinguishes between patients with and without HCC recurrence after LT. This was followed by the validation in a separate cohort of 59 HCC patients who underwent living related LT. The functions and potential gene targets of the recurrence-specific miRs were analysed using a database, clinical samples and HCC cell lines.

Results: We found that miR-718 showed significantly different expression in the serum exosomes of HCC cases with recurrence after LT compared with those without recurrence. Decreased expression of miR-718 was associated with HCC tumour aggressiveness in the validated cohort series. We identified HOXB8 as a potential target gene of miR-718, and its upregulation was associated with poor prognosis.

Conclusion: Circulating miRs in serum exosomes have potential as novel biomarkers for predicting HCC recurrence.

Citing Articles

Delivering miR-23b-3p by small extracellular vesicles to promote cell senescence and aberrant lipid metabolism.

Jin Y, Sun G, Chen B, Feng S, Tang M, Wang H BMC Biol. 2025; 23(1):41.

PMID: 39934790 PMC: 11817603. DOI: 10.1186/s12915-025-02143-9.

Novel biomarkers for monitoring and management of hepatocellular carcinoma.

Solhi R, Pourhamzeh M, Zarrabi A, Hassan M, Mirzaei H, Vosough M Cancer Cell Int. 2024; 24(1):428.

PMID: 39719624 PMC: 11668010. DOI: 10.1186/s12935-024-03600-1.

Unlocking the Secrets of Extracellular Vesicles: Orchestrating Tumor Microenvironment Dynamics in Metastasis, Drug Resistance, and Immune Evasion.

Mir R, Baba S, Elfaki I, Algehainy N, Alanazi M, Altemani F J Cancer. 2024; 15(19):6383-6415.

PMID: 39513123 PMC: 11540496. DOI: 10.7150/jca.98426.

Current updates on the molecular and genetic signals as diagnostic and therapeutic targets for hepatitis B virus-associated hepatic malignancy.

Adugna A, Muche Y, Melkamu A, Jemal M, Belew H, Amare G Heliyon. 2024; 10(14):e34288.

PMID: 39100497 PMC: 11295980. DOI: 10.1016/j.heliyon.2024.e34288.

Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases.

Xu C, Jiang C, Li Z, Gao H, Xian J, Guo W MedComm (2020). 2024; 5(8):e660.

PMID: 39015555 PMC: 11247338. DOI: 10.1002/mco2.660.

References

Mazzaferro V, Chun Y, Poon R, Schwartz M, Yao F, Marsh J . Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008; 15(4):1001-7. PMC: 2266786. DOI: 10.1245/s10434-007-9559-5. View

Hu G, Drescher K, Chen X . Exosomal miRNAs: Biological Properties and Therapeutic Potential. Front Genet. 2012; 3:56. PMC: 3330238. DOI: 10.3389/fgene.2012.00056. View

Hu Q, Jiang H, Su J, Jia Y . MicroRNAs as biomarkers for hepatocellular carcinoma: a diagnostic meta-analysis. Clin Lab. 2013; 59(9-10):1113-20. DOI: 10.7754/clin.lab.2012.121102. View

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J, Lotvall J . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654-9. DOI: 10.1038/ncb1596. View

Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G . Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6):883-91. PMC: 3645291. DOI: 10.1038/nm.2753. View

Mathivanan S, Fahner C, Reid G, Simpson R . ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2011; 40(Database issue):D1241-4. PMC: 3245025. DOI: 10.1093/nar/gkr828. View

Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F . MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011; 17(9):2725-33. DOI: 10.1158/1078-0432.CCR-10-2132. View

Katsuda T, Kosaka N, Ochiya T . The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers. Proteomics. 2013; 14(4-5):412-25. DOI: 10.1002/pmic.201300389. View

Cereghetti D, Lee P . Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism. Microrna. 2014; 2(3):194-204. DOI: 10.2174/22115366113029990012. View

10.

Liu A, Yao T, Wang W, Wong K, Lee N, Fan S . Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012; 2(2):e000825. PMC: 3308260. DOI: 10.1136/bmjopen-2012-000825. View

11.

Wang H, Hou L, Li A, Duan Y, Gao H, Song X . Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014; 2014:864894. PMC: 4052145. DOI: 10.1155/2014/864894. View

12.

Barry C, DSouza M, McCall M, Safadjou S, Ryan C, Kashyap R . Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant. 2011; 12(2):428-37. DOI: 10.1111/j.1600-6143.2011.03788.x. View

13.

Shah N, Sukumar S . The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010; 10(5):361-71. DOI: 10.1038/nrc2826. View

14.

Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D . Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem. 2013; 288(37):26888-97. PMC: 3772238. DOI: 10.1074/jbc.M113.452458. View

15.

Qi P, Cheng S, Wang H, Li N, Chen Y, Gao C . Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011; 6(12):e28486. PMC: 3234251. DOI: 10.1371/journal.pone.0028486. View

16.

Llovet J . Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005; 40(3):225-35. DOI: 10.1007/s00535-005-1566-3. View

17.

Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H . Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res. 2005; 11(8):2889-93. DOI: 10.1158/1078-0432.CCR-04-2281. View

18.

Wang L, Yao M, Dong Z, Zhang Y, Yao D . Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2013; 35(1):9-20. PMC: 3907675. DOI: 10.1007/s13277-013-1141-0. View

19.

Qu K, Zhang K, Li H, Afdhal N, Albitar M . Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011; 45(4):355-60. DOI: 10.1097/MCG.0b013e3181f18ac2. View

20.

Hagiwara K, Ochiya T, Kosaka N . A paradigm shift for extracellular vesicles as small RNA carriers: from cellular waste elimination to therapeutic applications. Drug Deliv Transl Res. 2014; 4(1):31-7. PMC: 3918124. DOI: 10.1007/s13346-013-0180-9. View